$7.41
+0.17
(+2.35%)▲
4.12%
Downside
Day's Volatility :8.68%
Upside
4.76%
47.77%
Downside
52 Weeks Volatility :74.51%
Upside
51.19%
Period | Verastem, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -24.62% | 0.0% | 0.0% |
6 Months | -33.84% | 2.2% | 0.0% |
1 Year | 1752.5% | -4.7% | -2.1% |
3 Years | 227.88% | 18.0% | -6.5% |
Market Capitalization | 179.7M |
Book Value | $3.29 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -3.89 |
PEG Ratio | -1.89 |
Wall Street Target Price | 28.79 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -33.85% |
Return On Equity TTM | -91.87% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 2.6M |
EBITDA | -77.7M |
Diluted Eps TTM | -3.89 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.47 |
EPS Estimate Next Year | -3.1 |
EPS Estimate Current Quarter | -0.84 |
EPS Estimate Next Quarter | -0.67 |
What analysts predicted
Upside of 288.53%
Sell
Neutral
Buy
Verastem, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Verastem, Inc. | 4.96% | -33.84% | 1752.5% | 227.88% | 66.89% |
![]() Moderna, Inc. | 9.42% | -35.83% | -54.97% | -49.47% | 333.33% |
![]() Regeneron Pharmaceuticals, Inc. | 0.6% | 13.15% | 9.35% | 68.7% | 124.16% |
![]() Novo Nordisk A/s | -4.03% | 23.9% | 55.84% | 186.15% | 330.1% |
![]() Seagen, Inc. | 0.86% | 10.81% | 80.8% | 20.4% | 259.73% |
![]() Vertex Pharmaceuticals Incorporated | -6.55% | 8.87% | 11.3% | 55.67% | 105.25% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Verastem, Inc. | NA | NA | -1.89 | -3.47 | -0.92 | -0.34 | 0.0 | 3.29 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -12.72 | -0.22 | -0.07 | 0.0 | 35.32 |
![]() Regeneron Pharmaceuticals, Inc. | 23.18 | 23.18 | 1.75 | 42.5 | 0.17 | 0.09 | 0.01 | 234.47 |
![]() Novo Nordisk A/s | 41.18 | 41.18 | 4.02 | 2.67 | 0.89 | 0.22 | 0.01 | 20.77 |
![]() Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
![]() Vertex Pharmaceuticals Incorporated | 26.38 | 26.38 | 0.5 | 15.04 | 0.23 | 0.14 | 0.0 | 64.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Verastem, Inc. | Buy | $179.7M | 66.89% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $30.4B | 333.33% | 24.73 | -38.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $88.5B | 124.16% | 23.18 | 30.47% |
![]() Novo Nordisk A/s | Buy | $459.0B | 330.1% | 41.18 | 35.11% |
![]() Seagen, Inc. | Hold | $40.2B | 259.73% | NA | -32.61% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $90.5B | 105.25% | 26.38 | 35.94% |
Viking Global Investors LP
Bvf Inc
Deerfield Management Co
Vivo Capital, LLC
Orbimed Advisors, LLC
Soleus Capital Management, L.P.
Verastem, Inc.’s price-to-earnings ratio stands at None
Read Moreverastem, inc. (nasdaq: vstm) is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. cancer stem cells are an underlying cause of tumor recurrence and metastasis. verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. for more information, please visit www.versatem.com
Organization | Verastem, Inc. |
Employees | 57 |
CEO | Mr. Brian M. Stuglik BPHARM, R.Ph., RPh |
Industry | Health Technology |
Asymmetric Smart Alpha S&p 500 Etf
$7.41
+2.35%
Advisorshares Alpha Dna Equity Sentiment Etf
$7.41
+2.35%
Falcon's Beyond Global Inc
$7.41
+2.35%
Jaguar Global Growth Corporation I
$7.41
+2.35%
Missfresh Ltd
$7.41
+2.35%
Shuaa Partners Acquisition Corp I
$7.41
+2.35%
Rose Hill Acquisition Corp
$7.41
+2.35%
Partners Bancorp
$7.41
+2.35%
Mercantile Bank Corp
$7.41
+2.35%